Study patients
breast cancer
ONCOLOGY, BREAST CANCER
Eligible patients were females between 18 and 75 years of age, diagnosed with Stage II–IV breast cancer in the adjuvant or metastatic setting with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and who were scheduled for myelotoxic TA regimen (75 mg/m